And you missed another point which is that investors making a $ or two while patients receive very little to no benefit and aren’t part of a study to create improved outcomes longer term aren’t getting healthcare dollars spent wisely or even perhaps ethically. Optune is not credited with extending survival the way L is by those who say there has been no improvement for many years in GBM or rGBM until L. This might be threatening to those who are invested in NVCR. Best wishes.
Market Data 
Markets 
AI
